Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A1 | P53985 | 19/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 10/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 9/20 | 0.52 |
| ▸ | SLC16A7 | O60669 | 1/20 | 0.52 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.35 |
| ▸ | CAMK2B | Q13554 | 1/20 | 0.35 |
| ▸ | HIPK4 | Q8NE63 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4796666 | 0.89 | SLC16A1 (0.70) | SLC16A1CYP2C9CYP3A4SLC16A7ABCB11 | |
| SCHEMBL4804324 | 0.88 | SLC16A1 (0.58) | SLC16A1CYP2C9CYP3A4SLC16A7ABCB11 | |
| SCHEMBL3826879 | 0.87 | SLC16A1 (0.60) | SLC16A1CYP2C9CYP3A4SLC16A7ALDH1A1 | |
| SCHEMBL4804904 | 0.87 | SLC16A1 (0.57) | SLC16A1CYP2C9CYP3A4SLC16A7ABCB11 | |
| SCHEMBL4804234 | 0.85 | SLC16A1 (0.56) | SLC16A1CYP2C9CYP3A4SLC16A7ABCB11 | |
| SCHEMBL5138945 | 0.85 | SLC16A1 (0.56) | SLC16A1CYP2C9CYP3A4SLC16A7ALDH1A1 | |
| SCHEMBL4802442 | 0.85 | SLC16A1 (0.57) | SLC16A1CYP2C9CYP3A4SLC16A7ABCB11 | |
| SCHEMBL4799484 | 0.80 | SLC16A1 (0.48) | SLC16A1CYP2C9CYP3A4SLC16A7ABCB11 | |
| SCHEMBL4913181 | 0.80 | SLC16A1 (0.49) | SLC16A1CYP2C9CYP3A4SLC16A7ABCB11 | |
| SCHEMBL3831983 | 0.79 | SLC16A1 (0.81) | SLC16A1CYP2C9CYP3A4SLC16A7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7361660-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2008-04-22 | — | — | US | disclosed |
| US-20040171623-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2004-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171623-A1 | Chemical compounds | CBR1, SETDB1, CBR3 | SLC16A1 1397/4885CYP2C9 63/4885CYP3A4 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.